$VCNX
Vaccinex Inc

2019 Q1 Form 10-K Financial Statement

#000156459019007458 Filed on March 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $94.00K $190.0K $724.0K
YoY Change -54.37% 111.11% 704.44%
Cost Of Revenue $175.0K $300.0K $1.033M
YoY Change -27.08% 87.5% 545.63%
Gross Profit -$81.00K -$110.0K -$309.0K
YoY Change 138.24% 57.14% 341.43%
Gross Profit Margin -86.17% -57.89% -42.68%
Selling, General & Admin $1.650M $1.380M $4.620M
YoY Change 35.25% 25.45% 3.13%
% of Gross Profit
Research & Development $7.412M $7.070M $22.35M
YoY Change 66.41% 40.56% 35.06%
% of Gross Profit
Depreciation & Amortization $60.00K $50.00K $223.0K
YoY Change 7.14% -16.67% 8.25%
% of Gross Profit
Operating Expenses $7.412M $8.460M $22.35M
YoY Change 66.41% 38.01% 35.06%
Operating Profit -$9.140M -$8.570M -$22.66M
YoY Change 60.1% 38.23% 36.35%
Interest Expense $0.00 $0.00 $392.0K
YoY Change -100.0% -100.0% -71.13%
% of Operating Profit
Other Income/Expense, Net $73.00K $110.0K $165.0K
YoY Change -621.43% -650.0% -512.5%
Pretax Income -$9.067M -$8.450M -$29.52M
YoY Change 15.33% 221.29% 57.35%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.067M -$8.450M -$29.52M
YoY Change 15.33% 226.25% 57.66%
Net Earnings / Revenue -9645.74% -4447.37% -4077.07%
Basic Earnings Per Share
Diluted Earnings Per Share -$790.1K -$736.1K -$2.571M
COMMON SHARES
Basic Shares Outstanding 11.48M 11.48M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.29M $19.72M $19.72M
YoY Change 286.64% 371.77%
Cash & Equivalents $5.279M $5.618M $5.620M
Short-Term Investments $2.350M $14.11M $14.11M
Other Short-Term Assets $830.0K $1.060M $1.060M
YoY Change 18.57% 55.88%
Inventory
Prepaid Expenses
Receivables $630.0K $639.0K $640.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.75M $21.42M $21.42M
YoY Change 243.67% 330.72% 330.99%
LONG-TERM ASSETS
Property, Plant & Equipment $540.0K $604.0K $600.0K
YoY Change -6.9% 0.5% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $540.0K $604.0K $610.0K
YoY Change -56.45% 0.5% 0.0%
TOTAL ASSETS
Total Short-Term Assets $12.75M $21.42M $21.42M
Total Long-Term Assets $540.0K $604.0K $610.0K
Total Assets $13.29M $22.03M $22.03M
YoY Change 168.48% 295.12% 294.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.440M $2.322M $2.320M
YoY Change 3.39% 21.57% 21.47%
Accrued Expenses $4.520M $4.364M $4.360M
YoY Change 65.57% 122.99% 122.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.960M $6.686M $6.690M
YoY Change 32.32% 60.53% 60.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.960M $6.686M $6.690M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.959M $6.686M $30.65M
YoY Change -73.75% -9.0% 58.73%
SHAREHOLDERS EQUITY
Retained Earnings -$225.8M -$216.8M
YoY Change 15.76%
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $11.00K $11.00K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$17.63M -$8.621M -$8.620M
YoY Change
Total Liabilities & Shareholders Equity $13.29M $22.03M $22.03M
YoY Change 168.57% 295.12% 294.8%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$9.067M -$8.450M -$29.52M
YoY Change 15.33% 226.25% 57.66%
Depreciation, Depletion And Amortization $60.00K $50.00K $223.0K
YoY Change 7.14% -16.67% 8.25%
Cash From Operating Activities -$8.476M -$7.560M -$25.28M
YoY Change 64.1% 20.96% 18.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$170.0K $235.0K
YoY Change -100.0% 245.59%
Acquisitions
YoY Change
Other Investing Activities $11.80M $2.080M -$14.01M
YoY Change
Cash From Investing Activities $11.80M $1.920M -$14.24M
YoY Change -25206.38% 20842.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 40.96M
YoY Change -100.0% -100.0% 70.83%
NET CHANGE
Cash From Operating Activities -8.476M -7.560M -25.28M
Cash From Investing Activities 11.80M 1.920M -14.24M
Cash From Financing Activities 0.000 0.000 40.96M
Net Change In Cash 3.324M -5.640M 1.438M
YoY Change -364.65% -250.4% -42.91%
FREE CASH FLOW
Cash From Operating Activities -$8.476M -$7.560M -$25.28M
Capital Expenditures $0.00 -$170.0K $235.0K
Free Cash Flow -$8.476M -$7.390M -$25.51M
YoY Change 62.62% 18.24% 18.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-18722000
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6101000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6702000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6324000
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5618000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4180000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
14106000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
639000
CY2018 dei Trading Symbol
TradingSymbol
0001205922
CY2018 dei Entity Registrant Name
EntityRegistrantName
Vaccinex, Inc.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001205922
CY2018Q2 dei Entity Public Float
EntityPublicFloat
0
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11475749
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q4 us-gaap Liabilities
Liabilities
6686000
CY2017Q4 us-gaap Liabilities
Liabilities
7347000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208156000
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
11000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216767000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8621000
CY2018Q4 us-gaap Minority Interest
MinorityInterest
23963000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15342000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22028000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
117000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1061000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
677000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
21424000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
4974000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
604000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
601000
CY2018Q4 us-gaap Assets
Assets
22028000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
319000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4165000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1957000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
298000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6686000
CY2017Q4 us-gaap Assets
Assets
5575000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2322000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1910000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4364000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4619000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4483000
CY2017Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
2813000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
369000
CY2017Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
111718000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
7684000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54123000
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
11000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187249000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-125453000
CY2017Q4 us-gaap Minority Interest
MinorityInterest
11963000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-113490000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5575000
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
66317000
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
53089959
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
53089796
CY2018Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2017Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
140261000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11476601
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1103396
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11475749
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1102560
CY2018Q4 us-gaap Treasury Stock Preferred Shares
TreasuryStockPreferredShares
0
CY2017Q4 us-gaap Treasury Stock Preferred Shares
TreasuryStockPreferredShares
163
CY2018Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
852
CY2017Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
836
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
724000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90000
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
1033000
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
160000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22353000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16551000
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
369000
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3743000
CY2018 us-gaap Interest Expense
InterestExpense
392000
CY2017 us-gaap Interest Expense
InterestExpense
1358000
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2379000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-29518000
CY2017 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
-3211000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
28005000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
21194000
CY2018 vcnx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-29518000
CY2017 vcnx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-21933000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.65
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.90
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5223635
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1101937
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-107065000
CY2017 us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
12000000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
111718000
CY2018 us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
12000000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2017 vcnx Temporary Equity Stock Issued Issuance Costs
TemporaryEquityStockIssuedIssuanceCosts
18000
CY2018 us-gaap Depreciation
Depreciation
223000
CY2017 us-gaap Depreciation
Depreciation
206000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
308000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1217000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
100000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
177000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
319000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
522000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
384000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
330000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
421000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-555000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2407000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-27000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-298000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
298000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25276000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21387000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20756000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6750000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
235000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
68000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14241000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68000
CY2017 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
9977000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
37125000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2675000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
CY2018 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
5500000
CY2017 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
6000000
CY2018 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
12000000
CY2017 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
12000000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40955000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23974000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1438000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2519000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1661000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
275000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
13000
CY2017 vcnx Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
9000
CY2018 vcnx Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
111718000
CY2018 vcnx Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
7684000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
206000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
236000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6928000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
223000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, the valuation of derivative instruments, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.</p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Other Risks and Uncertainties</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits the cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company&#8217;s product candidates and adversely impact its results of operations.</p>
CY2018 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2018Q4 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
3796000
CY2017Q4 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
891000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
296000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
311000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
239000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
36000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
324000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
192000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14106000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2018 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2018 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Lesser of estimated useful life or remaining lease term
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0
CY2018 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0
CY2018Q4 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
0
CY2018Q4 us-gaap Income Tax Examination Penalties Accrued
IncomeTaxExaminationPenaltiesAccrued
0
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
14106000
CY2016Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
694000
CY2017 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
3418000
CY2017 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
-3743000
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
369000
CY2018 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
-369000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
CY2018Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
308000
CY2016Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
31000
CY2018Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2017Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11000
CY2017 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2018 vcnx Royalty Payments Percent Of Net Sales
RoyaltyPaymentsPercentOfNetSales
0.01
CY2018Q4 vcnx Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
14000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
168000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
140000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
168000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
168000
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3350046
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9341111
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
405658
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
33976
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2037
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16641
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
420956
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
30000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
700
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
44573
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
405683
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
366463
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.01
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.60
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.10
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.60
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.20
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.10
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.10
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.10
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.69
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.46
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1978000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5021000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.87
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.00
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
234466
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
300000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
29000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
435639
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
216000
CY2018 vcnx Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumContractualTerm
P10Y
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
177000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
319000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 vcnx Tax Cuts And Jobs Act Change In Tax Rate Deferred Tax Assets Provisional Income Tax Benefit
TaxCutsAndJobsActChangeInTaxRateDeferredTaxAssetsProvisionalIncomeTaxBenefit
20700000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.103
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.054
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.103
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.170
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.004
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
696000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
696000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10700000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-10000000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57026000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.361
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.532
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
52362000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45057000
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
14592000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
11542000
CY2018Q4 vcnx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
468000
CY2017Q4 vcnx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
504000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
56000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
115000
CY2017Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
96000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
78000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
202000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
330000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
67680000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57722000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67680000
CY2018 us-gaap Tax Credit Carryforward Expiration Date
TaxCreditCarryforwardExpirationDate
2021-12-31
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
from January 1, 2015 to December 31, 2018
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3211000
CY2018 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00

Files In Submission

Name View Source Status
0001564590-19-007458-index-headers.html Edgar Link pending
0001564590-19-007458-index.html Edgar Link pending
0001564590-19-007458.txt Edgar Link pending
0001564590-19-007458-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ge0q5qcbv5tv000001.jpg Edgar Link pending
ge0q5qcbv5tv000002.jpg Edgar Link pending
ge0q5qcbv5tv000003.jpg Edgar Link pending
ge0q5qcbv5tv000004.jpg Edgar Link pending
ge0q5qcbv5tv000005.jpg Edgar Link pending
ge0q5qcbv5tv000006.jpg Edgar Link pending
ge0q5qcbv5tv000007.jpg Edgar Link pending
ge0q5qcbv5tv000008.jpg Edgar Link pending
ge0q5qcbv5tv000009.jpg Edgar Link pending
ge0q5qcbv5tv000010.jpg Edgar Link pending
ge0q5qcbv5tv000011.jpg Edgar Link pending
ge0q5qcbv5tv000012.jpg Edgar Link pending
ge0q5qcbv5tv000013.jpg Edgar Link pending
ge0q5qcbv5tv000014.jpg Edgar Link pending
ge0q5qcbv5tv000015.jpg Edgar Link pending
ge0q5qcbv5tv000016.jpg Edgar Link pending
ge0q5qcbv5tv000017.jpg Edgar Link pending
ge0q5qcbv5tv000018.jpg Edgar Link pending
ge0q5qcbv5tv000019.jpg Edgar Link pending
ge0q5qcbv5tv000020.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vcnx-10k_20181231.htm Edgar Link pending
vcnx-20181231.xml Edgar Link completed
vcnx-20181231.xsd Edgar Link pending
vcnx-20181231_cal.xml Edgar Link unprocessable
vcnx-20181231_def.xml Edgar Link unprocessable
vcnx-20181231_lab.xml Edgar Link unprocessable
vcnx-20181231_pre.xml Edgar Link unprocessable
vcnx-ex1024_1215.htm Edgar Link pending
vcnx-ex231_1084.htm Edgar Link pending
vcnx-ex311_1083.htm Edgar Link pending
vcnx-ex312_1082.htm Edgar Link pending
vcnx-ex321_1081.htm Edgar Link pending